眼保全手术联合辅助粒子放疗治疗眼眶恶性肿瘤的疗效：一项回顾性研究。
Outcomes of orbital malignancies treated with eye-sparing surgery and adjuvant particle radiotherapy: a retrospective study.
机构信息
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China.
Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, 4365 Kangxin Road, Pudong, Shanghai, 201321, China.
出版信息
BMC Cancer. 2019 Aug 6;19(1):776. doi: 10.1186/s12885-019-5964-y.
BACKGROUND
To report the clinical experience of eye sparing surgery (ESS) and adjuvant carbon-ion or proton radiotherapy (CIRT or PRT) for orbital malignancies.
METHODS
An analysis of the retrospective data registry from the Shanghai Proton and Heavy Ion Center for patients with orbital tumors was conducted. The 2-year local progression-free, regional recurrence-free, distant metastasis-free, progression-free, and overall survival (LPFS, RRFS, DMFS, PFS, OS) rates as well as associated prognostic indicators were analyzed. Radiotherapy-induced acute and late toxicities were summarized.
RESULTS
Between 7/2014 to 5/2018, 22 patients with orbital malignancies of various pathologies received ESS followed by CIRT (18), PRT (1), or PRT + CIRT boost (3). With a median follow-up of 20.25 (range 3.8-38.8) months, the 2-year OS, PFS, LPFS, RRFS, and DMFS rates were 100, 57.9, 92.9, 93.3, and 72.8%, respectively. No acute severe (i.e., ≥grade 3) toxicity was observed. Two patients experienced severe visual impairment as late toxicities.
CONCLUSION
With few observed acute and late toxicities, particle radiotherapy following ESS provided effective local control with infrequent severe toxicities for patients with orbital malignancies.
背景
报告眼眶恶性肿瘤行保眶手术（ESS）联合碳离子或质子调强放疗（CIRT 或 PRT）的临床经验。
方法
对上海质子重离子医院眼眶肿瘤患者的回顾性数据登记进行分析。分析 2 年局部无进展生存期（LPFS）、区域无复发生存期（RRFS）、无远处转移生存期（DMFS）、无进展生存期（PFS）和总生存期（OS）的累积率及相关预后指标，并总结放疗相关的急性和晚期毒性。
结果
2014 年 7 月至 2018 年 5 月，22 例不同病理眼眶恶性肿瘤患者行 ESS 后，分别接受 CIRT（18 例）、PRT（1 例）或 PRT+CIRT 推量（3 例）。中位随访时间为 20.25 个月（范围 3.8-38.8 个月），2 年 OS、PFS、LPFS、RRFS 和 DMFS 分别为 100%、57.9%、92.9%、93.3%和 72.8%。未观察到≥3 级急性重度毒性。2 例患者发生晚期严重视力损害。
结论
ESS 后行粒子放疗，急性和晚期毒性反应轻微，为眼眶恶性肿瘤患者提供了有效的局部控制，严重毒性反应罕见。
Zotero 插件